AbbVie Inc (NYSE: ABBV) announced on Friday the declaration by its board of directors of a quarterly cash dividend of USD1.07 per share.
This cash dividend is payable on 15 November 2019 to stockholders of record at the close of business on 15 October 2019.
The company added that since its inception in 2013, it has increased its dividend by 168%.
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025